Document:

Exhibit 10.2

 

WAIVER AND ASSIGNMENT OF REGISTRATION
RIGHTS AND VOTING AGREEMENT

This WAIVER AND ASSIGNMENT
OF REGISTRATION RIGHTS AND VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 22, 2020, by and
among GSK Finance (No.3) plc, a public limited company incorporated under the laws of England and Wales (“GSK Finance”),
Glaxo Group Limited (“GGL”) and Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Company”
and with GSK Finance and GGL, each a “Party”).

RECITALS

WHEREAS, GSK Finance
will acquire 9,644,807 ordinary shares of the Company, $0.00001 par value per share (the “Theravance Shares”)
from GGL pursuant to the share purchase agreement entered into between GGL and GSK Finance dated June 12, 2020 (the “Share
Purchase”), in connection with the Offering (as defined below);

 

WHEREAS, on the date
hereof, GSK Finance is issuing $280,336,000 Exchangeable Senior Notes Due 2023 (the “Notes”), guaranteed on
a senior basis by GlaxoSmithKline plc, exchangeable into substantially all of the Theravance Shares (the “Offering”).
The Notes will mature on June 22, 2023 (the “Maturity Date”);

 

WHEREAS, the Company
and GGL are party to the Registration Rights Agreement dated March 3, 2014, as amended on February 10, 2020 (the “Registration
Rights Agreement”), pursuant to which GGL has certain notice and registration rights;

 

WHEREAS, GSK Finance
is a wholly-owned subsidiary and an Affiliate of GGL;

 

WHEREAS, in connection
with the Share Purchase, GGL desires to assign its rights under the Registration Rights Agreement to GSK Finance (the “Assignment”)
and concurrently notify the Company in writing of such Assignment in accordance with Section 1.11 of the Registration Rights Agreement;

WHEREAS, in connection
with the Offering, GGL and GSK Finance desire to waive their registration rights under the Registration Rights Agreement, subject
to the terms and conditions herein;

WHEREAS, in connection
with the Offering, the Company is entering into a registration rights agreement on the date hereof (the “Additional Registration
Rights Agreement”) with the investors in the Notes in respect of the Theravance Shares deliverable upon exchange of the
Notes; and

WHEREAS, the Parties
desire to enter into this Agreement on the terms and conditions concerning the voting of all Voting Shares owned by GGL, GSK Finance
or their controlled Affiliates, and the waiver of their registration rights under the Registration Rights Agreement, subject to
the terms and conditions herein.

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual promises and agreements contained herein, each Party hereby agrees as follows:

 

ARTICLE I

WAIVER AND ASSIGNMENT OF RIGHTS UNDER
THE REGISTRATION RIGHTS AGREEMENT

Section 1.1. Assignment.

GGL hereby assigns its rights under the Registration
Rights Agreement to GSK Finance in accordance with Section 1.11 of the Registration Rights Agreement and GSK Finance hereby agrees
to be bound by and subject to the terms and conditions of the Registration Rights Agreement, including without limitation the provisions
of Section 1.12 thereof. In accordance with Section 1.11 of the Registration Rights Agreement, the following information is provided
to the Company with respect to GSK Finance:

 

		•	Legal
                                         name: GSK Finance (No.3) plc
	 	 	 
		•	Address:
                                         980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
	 	 	 
		•	Securities
                                         with respect to which GGL’s registration rights are being assigned: 9,644,807 ordinary
                                         shares of Theravance Biopharma, Inc., par value $0.00001 per share

 

     

     

    

 

Section 1.2. Waiver of Rights under Section
1 of the Registration Rights Agreement.

 

(a)       Each
of GGL and, with effect from the date on which GSK Finance is included as the registered holder of the Theravance Shares on the
Company’s register of shareholders pursuant to the Share Purchase, GSK Finance hereby waives all of its rights under Section
1 of the Registration Rights Agreement. Except as expressly set forth herein, GGL and GSK Finance are not waiving any right or
remedy under the Registration Rights Agreement, which remains in full force and effect in accordance with its terms. 

 

(b)       The
waiver pursuant to Section 1.2(a) above shall terminate with immediate effect upon the earlier of (i) the maturity date of the
Notes; (ii) any such other date on which the Notes are no longer issued and outstanding; or (iii) at any time that GGL or GSK Finance,
as the case may be, determines that it can no longer continue to own the shares under applicable laws or regulations. 

 

Section 1.3. Consent to New Registration
Right Agreement.

 

Each of GGL and GSK Finance hereby consent
to the entry into the Additional Registration Rights Agreement.

 

ARTICLE II

VOTING AGREEMENT

Section 2.1. Voting.

 

(a)       Except
as set forth in Section 2.1(b), GGL and GSK Finance shall ensure that all Voting Shares owned by GGL, GSK Finance or their controlled
Affiliates shall be voted on all matters, at the election of GSK Finance, either (i) in accordance with the recommendation of the
Independent Directors of the Board or (ii) in proportion to the votes cast by the other holders of the Company’s Voting Shares.

 

(b)       GGL
and GSK Finance shall ensure that all Voting Shares owned by GGL, GSK Finance or their controlled Affiliates are voted as set forth
in 2.1(a), unless the matter being voted upon involves any of the following:

 

		(i)	any proposal to issue Equity Securities to one or more parties in one transaction or a series of
transactions that result in any Person or group (within the meaning of Section 13(d)(3) of the Exchange Act) other than GSK Finance
and its Affiliates owning or having the right to acquire or intent to acquire beneficial ownership of Equity Securities with aggregate
voting power of greater than 20% or more of the aggregate voting power of all outstanding Equity Securities (for the avoidance
of doubt, in no event shall any such proposed issuance covered by this clause (ii) include a sale of the Company’s securities
in a public offering); or

 

		(ii)	any Change in Control.

 

(c)       Each
of GGL and GSK Finance hereby, on behalf of itself and its controlled Affiliates, appoints the Board as its proxy and each of GGL
and GSK Finance hereby, on behalf of itself and its controlled Affiliates, grants to the Board an irrevocable proxy to vote, or
execute and deliver written consents or otherwise act with respect to all Voting Shares of the Company now owned or hereafter acquired
by GGL, GSK Finance or their controlled Affiliates in the manner in which each of GGL and GSK Finance is obligated to vote, consent
or act pursuant to this Section 2.1. According to such proxy, each of GGL and GSK Finance, on behalf of itself and its controlled
Affiliates, hereby directs the Board to vote in accordance with the recommendation of the Independent Directors of the Board, unless
and until GSK Finance notifies the Board otherwise. Such proxy shall be irrevocable until this Agreement terminates pursuant to
its terms in Section 2.2 or this Section 2.1 is amended to remove such grant of proxy, and is coupled with an interest in all Voting
Shares of the Company owned by GGL, GSK Finance or their controlled Affiliates. This Agreement shall constitute the proxy granted
pursuant hereto.

 

     

     

    

 

Section 2.2. Termination.

The voting agreement as set forth in
Section 2.1 above shall terminate at the earliest of (i) the Maturity Date, (ii) a change in the composition of more than 50% of
the members of the Board as of the date hereof and (iii) the effective time of a Change in Control.

ARTICLE III

MISCELLANEOUS

Section 3.1. Notices.

If to Theravance:

 

Theravance Biopharma, Inc.

PO Box 309

Ugland House, South Church Street

George Town, Grand Cayman, Cayman
Islands

Attn: Office of General Counsel

Tel: +1 650 808 6000

Email: legal@theravance.com

 

With a copy to:

 

Theravance Biopharma, Inc.

c/o Theravance Biopharma US, Inc.

901 Gateway Boulevard

South San Francisco, CA 94080

Attention: Office of General Counsel

 

Skadden, Arps, Meagher & Flom
LLP

525 University Avenue

Palo Alto, California 94301-1908

Attn: Amr Razzak

Tel: +1 650 470 4533

Email: amr.razzak@skadden.com

 

Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP

550 Allerton Street

Redwood City, California 94063

Attn: Jeffrey Vetter

Tel: +1 650 321-2400

Email: jvetter@gunderson.com

 

If to GSK Finance:

 

GSK Finance (No.3) plc

980 Great West Road

Brentford, London

TW8 9GS

United Kingdom

Attn: Victoria Whyte

Tel: +44 20 8047 5000

Email: company.secretary@gsk.com

 

     

     

    

 

With a copy to:

 

GlaxoSmithKline plc

980 Great West Road

Brentford, London

TW8 9GS

United Kingdom

Attn: Victoria Whyte

Tel: +44 20 8047 5000

Email: company.secretary@gsk.com

 

and with a
copy to:

 

Cleary Gottlieb Steen & Hamilton
LLP

2 London Wall Place

London EC2Y 5AU

United Kingdom

Attn: Sebastian R. Sperber

Tel: +44 20 7614 2237

Email: ssperber@cgsh.com

 

or such other address or email address as such
party may hereafter specify for the purpose by notice to the other parties hereto. All notices required or permitted hereunder
shall be in writing and shall be deemed effectively given upon the earlier to occur of actual receipt or (i) upon personal delivery
to the party to be notified, (ii) when sent by confirmed electronic mail if sent during normal business hours of the recipient,
or if not, then on the next Business Day or (iii) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt.

 

Section 3.2. Amendments; Waivers.

 

(a)       Any
provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the
case of an amendment, by GGL, GSK Finance and the Company, or in the case of a waiver, by the party against whom the waiver is
to be effective; provided that, in the case of the Company, no such amendment or waiver shall be effective without the approval
of a majority of the Independent Directors.

 

(b)       No
failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided
by law.

 

Section 3.3. Successors and Assigns.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns; provided that no party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement
without the written consent of the other party hereto.

 

Section 3.4. Governing Law. This Agreement
shall be governed by and construed in accordance with and governed by the law of the State of Delaware, without regard to the conflicts
of laws principles thereof. Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of
Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect
of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees not to assert,
as a defense in any action, suit or proceeding in which any such claim is made that it is not subject thereto or that such action
suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof may not be appropriate or
that this agreement may not be enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of
the State of Delaware jurisdiction over such parties and over the subject matter of any such claim and agree that mailing of process
or other papers in connection with any such action, suit or proceeding in the manner provided in Section 3.1, or in such other
manner as may be permitted by law, shall be valid and sufficient thereof.

 

     

     

    

  

Section 3.5. Counterparts; Effectiveness.
This Agreement may be executed in any number of counterparts, each of which, when executed, shall be deemed to be an original and
which together shall constitute one and the same document.

 

Section 3.6. Specific Performance. Each
party acknowledges and agrees that their respective remedies at law for a breach or threatened breach of any of the provisions
of this Agreement would be inadequate and, in recognition of that fact, agrees that, in the event of a breach or threatened breach
by the Company, on the one hand, or GSK Finance, on the other hand, of the provisions of this Agreement, in addition to any remedies
at law, GSK Finance and the Company, respectively, without posting any bond shall be entitled to obtain equitable relief in the
form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy
which may then be available.

 

Section 3.7. Severability. In the event
of the invalidity of any provisions of this Agreement or if this Agreement contains any gaps, the parties agree that such invalidity
or gap shall not affect the validity of the remaining provisions of this Agreement. The parties will replace an invalid provision
or fill any gap with valid provisions which most closely approximate the purpose and economic effect of the invalid provision or,
in case of a gap, the parties’ presumed intentions. In the event that the terms and conditions of this Agreement are materially
altered as a result of the preceding sentences, the parties shall renegotiate the terms and conditions of this Agreement in order
to resolve any inequities. Nothing in this Agreement shall be interpreted so as to require either party to violate any applicable
laws, rules or regulations.

 

Section 3.8. Certain Definitions. As
used in this Agreement, the following terms shall have the following meanings:

 

“Affiliate” of a party means any
Person, whether de jure or de facto, which directly or indirectly controls, is controlled by, or is under common control with such
Person for so long as such control exists, where “control” means the decision-making authority as to such Person and,
further, where such control shall be presumed to exist where a Person owns more than fifty percent (50%) of the equity (or such
lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power
to vote on or direct the affairs of the entity; it being specified that for purposes of this Agreement, the Company and its direct
and indirect subsidiaries, if any, shall not be deemed to be Affiliates of GSK Finance.

 

“Board” means the Board of Directors
of the Company.

 

“Business Day”
means any day other than a Saturday, a Sunday or a day on which the Securities Exchange Commission is closed or on which banks
in the State of Delaware are required or authorized by law to be closed.

“Change in Control” means, with
respect to (A) the Company, any transaction or series of related transactions (including mergers, consolidations and other forms
of business consolidations) following which continuing shareholders of the Company hold less than 50% of the outstanding voting
securities of either the Company, the entity surviving such transaction or any direct or indirect parent entity of such continuing
or surviving entity or (B) the sale, lease, license, transfer or other disposal of all or substantially all of the business or
assets of the Company other than to a Person that is and for so long as it continues to be majority owned and controlled, directly
or indirectly, subsidiary of the Company.

 

“Equity Security” means any (i)
Voting Shares of the Company, (ii) securities of the Company convertible into or exchangeable for Voting Shares and (iii) options,
rights and warrants issued by the Company to subscribe for or acquire Voting Shares.

 

“Exchange Act” means the Securities
Exchange Act of 1934, as amended.

 

“Independent Director” shall mean
a director who complies with the independence requirements for directors with respect to the Company (without reference to any
applicable exemptions from such requirements) for companies listed on Nasdaq. For the avoidance of doubt, a person affiliated with
GGL or GSK Finance may not be an Independent Director.

 

“Person” means any natural person,
corporation, general partnership, limited partnership, limited liability company, joint venture, proprietorship or other business
organization.

 

“Voting Shares” shall mean the
ordinary shares of the Company and any other outstanding securities of the Company having the right to vote generally in any appointment
of directors of the Board.

 

Section 3.9. Captions. The captions,
headings and arrangements used in this Agreement are for convenience only and do not in any way limit or amplify the terms and
provisions hereof.

 

[Signature page follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as
of the day and year first above written.

 

	 	THERAVANCE BIOPHARMA, INC.
	 	 
	 	 
	 	By:	/s/
    Rick E Winningham
	 	 	Name:
    Rick E Winningham
	 	 	Title:
    Chief Executive Officer
	 	 	 
	 	 	 
	 	GSK FINANCE (NO.3) PLC
	 	 
	 	 
	 	By:	/s/ P.
    K. Hopkins
	 	 	Name: P. K. Hopkins
	 	 	Title: Director
	 	 	 
	 	 	 
	 	GLAXO GROUP LIMITED
	 	 	 
	 	 	 
	 	By:	/s/
    John Sadler
	 	 	Name: John Sadler
	 	 	Title: Authorized Signatory for and on behalf
    of The Wellcome Foundation Limited Corporate DirectorExhibit 10.3

 

COOPERATION AGREEMENT

 

This COOPERATION AGREEMENT
(this “Agreement”) is entered into as of June 22, 2020, by and among Theravance
BIOPHARMA, Inc. (the “Company”), GlaxoSmithKline plc (“GSK”)
and GSK FINANCE (NO.3) PLC (the “Issuer”).

 

WHEREAS, on the date
hereof, the Issuer has issued $280,336,000 Exchangeable Senior Notes due 2023 (the “Notes”) exchangeable into
9,644,792 ordinary shares of the Company currently owned indirectly by GSK (the “Shares”), guaranteed on a senior
basis by GSK, pursuant to an indenture dated as of the date hereof by and among GSK, the Issuer and Deutsche Bank Trust Company
Americas, as trustee (as in effect on the date hereof, the “Indenture”);

 

WHEREAS, on the date
hereof, the Company, GSK and the Issuer have entered into a registration rights agreement to provide for resale registration rights
for the Holders (the “Registration Rights Agreement”); and

 

WHEREAS, the Company,
GSK and the Issuer desire to enter into this Agreement on the terms and conditions set forth herein concerning the exercise of
the Cash Settlement Option and the exercise of resale registration rights by Holders pursuant to the Registration Rights Agreement;

 

NOW, THEREFORE, the
parties hereto hereby agree as follows:

 

1.           Cash
Settlement Option. 

 

		a.	The Issuer shall, subject to the next sentence, deliver to Holders that exercise their Exchange
Rights their pro rata share of the Exchange Property in satisfaction of any such exercise. The Issuer may exercise the Cash
Settlement Option (i) where the Notes submitted for exchange on the relevant Exercise Date have an aggregate principal amount of
less than $1,000,000; provided that the aggregate cash amount delivered upon such exchanges shall not exceed $22,000,000;
or (ii) solely to the extent that, in its reasonable judgment, it is unable to satisfy such Exchange Right through the delivery
of the relevant pro rata share of the Exchange Property due to practical difficulties on the Exercise Date that cannot be resolved
through the Issuer using its commercially reasonable efforts at the time that the Exchange Property is required to be delivered
to such Holders.

		b.	The Issuer shall deliver to Holders that exercise their Exchange Right on or after the delivery
of a Redemption Notice (other than a redemption pursuant to Section 5.7(b) of the Indenture) by the Issuer until (and including)
the Redemption Date their pro rata share of the Exchange Property in satisfaction of any such exercise and will not exercise the
Cash Settlement Option in relation to such exchanges.

		c.	The Issuer will not redeem the Notes pursuant to the provisions of Section 5.7 of the Indenture
during any period in relation to which the Company has notified the Holders pursuant to Sections 3(e), 3(f) and 3(g) of the Registration
Rights Agreement that resales of Registrable Securities (as defined in the Registration Rights Agreement) are suspended. The Company
will give the Issuer notice of any such suspension at the same time that it gives notice thereof to Holders.

2.           Notifications
to the Company. The Issuer will provide notice to the Company of the following:

 

		a.	any election by the Issuer to exercise the Cash Settlement Option;

		b.	the relevant pro rata share of the Exchange Property to be delivered to a Holder upon any
exercise of its Exchange Right, including the amount of any cash payment to such Holder in lieu of fractional Shares in accordance
with Section 3(a) below;

		c.	the delivery of any Redemption Notice to the Holders (to be delivered to the Company one business
day in advance of delivery to Holders);
	 	 	 

     

     

    

 

		d.	the occurrence of any events that the Issuer reasonably expects to affect the Issuer’s ability
to deliver the Exchange Property;
	 	 	 

		e.	when any notice from the Issuer is delivered to Holders; and
	 	 	 

		f.	any amendment to the Indenture.

3.          Confirmation
of Exchange Notice; Delivery of Transfer Requests.

 

		a.	Subject to the next sentence, within two (2) Business Days following the receipt of an Exchange
Notice from Holders exercising their Exchange Rights, the Issuer will provide written notice to the Company of the number of Shares
that will be delivered to the exchanging Holder. If any Exchange Notice is received by the Issuer (i) after March 22, 2023 or (ii)
at least five (5) Business Days prior to the applicable Redemption Date, then the Issuer will provide to the Company, not later
than 5:00 p.m. (Eastern) on the fourth (4th) Business Day prior to the Maturity Date or the Redemption Date, as applicable,
a schedule containing the names of all the exchanging Holders and the respective number of Shares to be delivered to each such
Holders.
	 	 	 

		b.	The Issuer will deliver a copy of any transfer request form delivered to Computershare, as transfer
agent in connection with the delivery of Shares to Holders upon exercises by Holders of their Exchange Rights, to the Company by
email to the email address specified below prior to or concurrently with the mailing or delivery of such transfer request form
to Computershare.

 

4.            Definitions.
Capitalized terms used and not defined herein shall have the respective meanings set forth in the Indenture.

 

5.            Notices.
All communications hereunder shall be in writing and shall be sent by confirmed electronic mail, mailed, hand delivered or couriered
and confirmed to the parties hereto as follows:

 

		a.	If to the Company:

 

Theravance Biopharma, Inc.

 

PO Box 309

Ugland House, South Church Street

George Town, Grand Cayman, Cayman Islands

Attn: Office of General Counsel

Tel: (650) 808-6000

Email: legal@theravance.com

 

with a copy to:

 

Theravance Biopharma, Inc.

c/o Theravance Biopharma US, Inc.

901 Gateway Boulevard

South San Francisco, CA 94080

Attention: Office of General Counsel

 

Skadden, Arps, Meagher & Flom LLP

525 University Avenue

Palo Alto, California 94301-1908

Attn: Amr Razzak

Tel: 650-470-4533

Email: amr.razzak@skadden.com

 

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian,
LLP

550 Allerton Street

Redwood City, California 94063

Attn: Jeffrey Vetter

Tel: 650-321-2400

Email: jvetter@gunderson.com

 

     

     

    

 

		b.	If to GSK and the Issuer:

 

GlaxoSmithKline plc

980 Great West Road

Brentford TW8 9GS

England

Attention: Victoria Whyte

Tel: +44 20 8047 5000

E-mail: company.secretary@gsk.com

 

with a copy to:

 

Cleary Gottlieb Steen & Hamilton LLP

2 London Wall Place

London EC2Y 5AU

England

Attn: Sebastian Sperber

Tel: +44 20 7614 2200

Email: ssperber@cgsh.com

 

Any party hereto may change the address or
email address for receipt of communications by giving written notice to the others.

 

6.              Applicable
Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts
made and to be performed within the State of New York.

 

7.             Counterparts.
This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be
deemed to be an original, but all such respective counterparts shall together constitute one and the same instrument.

 

[Signature page follows.]

 

     

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Agreement as of the date first set forth above.

 

	 	THERAVANCE
    BIOPHARMA, INC.
	 	 
	 	 
	 	By:
    	/s/
    Rick E Winningham
	 	 	Name:
    Rick E Winningham
	 	 	Title:
    Chief Executive Officer
	 	 
	 	 
	 	GLAXOSMITHKLINE
    PLC
	 	 
	 	 
	 	By:	/s/
    P. K. Hopkins
	 	 	Name:
    P. K. Hopkins
	 	 	Title:  Authorized
    Signatory

 

 

	 	GSK
    FINANCE (NO.3) PLC
	 	 
	 	 
	 	By:	/s/
    P. K. Hopkins
	 	 	Name:
    P. K. Hopkins
	 	 	Title:
    Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]